Latest Views & News

Immunocore announces good news - Neil Woodford can breathe a sigh of relief, for now

By Nigel Somerville | Tuesday 20 November 2018


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Privately held Immunocore, which forms part of the Neil Woodford estate, has announced some good news: it has signed a deal with Genetech, part of Roche Group, for the development of Immunocore’s IMC-C103C drug aimed at targeting the MAGE-A4 protein (Melanoma-Associated Antigen A4). The really good news is that Genetech is to hand over $100 million in upfront and near-term milestone payments, and upon establishing proof-of-concept there is an option to co-develop the treatment or license the treatment to Genetech for royalty and milestone payments. Needless to say, Woodford Patient Capital Trust (WPCT) rushed out a statement too...

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

SAGA

The ongoing saga of woe at Saga

 

Quiz

The ShareProphets Sunday Pub Quiz #160

 

VCP

Gyrations at Victoria Carpets

 

MADE

GOTCHA: Made.com admits it is fucked

 

Bull

Stuff happens but we are not stuffed

 

Quiz

The ShareProphets Sunday Pub Quiz #159

 

OCDO

Challenges continue at Ocado

 

ICON

Iconic Labs – back from the dead?

 

PUR

Pure Gold – Pure Ramping!

Sunday »

Quiz

The ShareProphets Sunday Pub Quiz #158

 

ORCA

Buy Orcadian Energy